| Name | Title | Contact Details |
|---|
Rolling Hills Memorial Park is a El Sobrante, CA-based company in the Business Services sector.
Welcome to Ecopetrol America Inc. Ecopetrol America Inc. (EAI) is a subsidiary of Ecopetrol S.A., the national oil company of the Republic of Colombia...
Letterhead Press is a New Berlin, WI-based company in the Business Services sector.
"Alliance Building Services is a premier provider of commercial services in the greater New York City area. As a leading provider of building services, we take pride in keeping your properties – and your people – safe and secure. We offer a family of services that includes First Quality Maintenance, Classic Security, Bright Star Messenger Centers, and Onyx Restoration and Painting. When you contract with Alliance, you know the job will be done, and done well – which gives you more time to concentrate on the business of your business."
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.